Metraipolis › archive › dc_08f7e4254eff

SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism for the treatment of… — Europe PMC PMID:42239508

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42239508
DOI
10.3389/fphar.2026.1824708
License (as archived)
solo-consultazione
Archived
2026-11-01T14:54:47.093Z
SHA-256 of the archived text
e0fdee0f9c3ce48f3bff16043b763a7d7433106e0b01093dc4f6c276bc268c24
Stable URL of this page
https://metraipolis.com/documento/dc_08f7e4254eff

How to cite

SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism for the treatment of… — Europe PMC PMID:42239508 — Europe PMC (en), https://europepmc.org/article/MED/42239508 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_08f7e4254eff (Metraipolis archive dc_08f7e4254eff, sha256 e0fdee0f9c3ce48f3bff16043b763a7d7433106e0b01093dc4f6c276bc268c24)
BibTeX
@misc{dc08f7e4254eff,
  title = {SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism for the treatment of… — Europe PMC PMID:42239508},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42239508},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_08f7e4254eff; sha256 e0fdee0f9c3ce48f3bff16043b763a7d7433106e0b01093dc4f6c276bc268c24},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42239508. Agents can read the archived copy with the MCP tool read_document.